Share on StockTwits
 

Research analysts at Roth Capital upped their price objective on shares of Keryx Biopharmaceuticals (NASDAQ:KERX) to $30.00 in a report released on Tuesday, Analyst Ratings.Net reports. Roth Capital’s target price suggests a potential upside of 97.11% from the stock’s previous close.

Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.19) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.11) by $0.08. During the same quarter last year, the company posted ($0.08) earnings per share.

KERX has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase & Co. reiterated a “positive” rating on shares of Keryx Biopharmaceuticals in a research note to investors on Thursday, November 7th. Separately, analysts at Brean Capital reiterated a “buy” rating on shares of Keryx Biopharmaceuticals in a research note to investors on Tuesday, November 5th. Finally, analysts at JMP Securities reiterated an “outperform” rating on shares of Keryx Biopharmaceuticals in a research note to investors on Monday, November 4th. They now have a $22.00 price target on the stock, up previously from $14.00. Eight equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and an average price target of $17.57.

Keryx Biopharmaceuticals, Inc (NASDAQ:KERX) is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.